nach oben

Erschienen in:

01.05.2012 | Preclinical study

Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy

verfasst von: C. Panis, A. C. S. A. Herrera, V. J. Victorino, F. C. Campos, L. F. Freitas, T. De Rossi, A. N. Colado Simão, A. L. Cecchini, R. Cecchini

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Several adverse effects of chemotherapy treatments have been described, and most of these effects are associated with direct interactions between blood cells and indirect effects generated during the oxidative metabolism of antineoplastic drugs. In this study we evaluated the oxidative systemic status and hematological profiles of breast cancer patients with advanced ductal infiltrative carcinoma treated with doxorubicin (DOX) or paclitaxel (PTX) within 1 h after chemotherapy. Blood analyses included evaluation of hemogram, pro-oxidative markers, and antioxidant status. The results showed that advanced breast cancer diseased (AD) patients without previous chemotherapy presented anemia and high oxidative stress status characterized by elevated levels of lipid peroxidation and nitric oxide, and reduced catalase activity when compared with controls. DOX-treated patients exhibited increased anemia and reduced antioxidant status, which was revealed by decreases in reduced glutathione levels and the total antioxidant capacity of plasma; however, these changes did not lead to further increases in lipid peroxidation or carbonyl proteins when compared with the AD group. PTX-treated patients also showed increased anemia, lactate dehydrogenase leakage, and enhanced lipid peroxidation. These data reveal for the first time that patients subjected to chemotherapy with DOX or PTX present immediate systemic oxidative stress and red blood cell oxidative injury with anemia development. These findings provide a new perspective on the systemic redox state of AD and patients subjected to chemotherapy regarding oxidative stress enhancement and its possible involvement in the aggravation of chronic anemia.

Loft S, Poulsen HE (1996) Cancer risk and oxidative DNA damage in man. J Mol Med 74:297–312PubMedCrossRef

Karihtala P, Soini Y (2007) Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 115:81–103PubMedCrossRef

National Comprehensive Cancer Network (NCCN) (2009) NCCN clinical practice guidelines in oncology: cancer and chemotherapy-induced anemia. NCCN, USA, vol 2, p 47

Saulter KH, Acharia CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A (2008) An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. Plos One 3(4):e1908CrossRef

Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK (2003) Protection against acute Adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidant s, inhibition of TNF-α expression. BMC Pharmacol 3:16PubMedCrossRef

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclins: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharm Rev 56(2):185–230PubMedCrossRef

Ramanathan B, Jan KY, Chen CH, Hour TZ, Yu HJ, Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65(18):8455–8460PubMedCrossRef

Doroshow JH, Davies KJA (1986) Redox cycling of anthracyclins by cardiac mitochondria: formation of superoxide anion, hydrogen peroxide and hydroxyl radical. J Biol Chem 261(7):3068–3074PubMed

Niki E (2009) Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med 47:469–484PubMedCrossRef

10.

Schrijvers D (2003) Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet 42(9):779–791PubMedCrossRef

11.

Alexandre J, Hu Y, Lu W, Pelicano H, Huang P (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67(8):3512–3517PubMedCrossRef

12.

Hadzic T, Aykin-Burns N, Zhu Y, Mitchell Z, Coleman MC, Leick K, Jacobson GM, Spitz DR (2010) Paclitaxel combined with inhibitors of glucose, hydroperoxide metabolism enhances breast cancer cell killing via H₂O₂-mediated oxidative stress. Free Radic Biol Med 48:1024–1033PubMedCrossRef

13.

Fukui M, Yamabe N, Zhu BT (2010) Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer 46(10):1882–1891PubMedCrossRef

14.

Mark M, Walter R, Osian-Meredith D, Reinhart WH (2001) Commercial taxane formulations induce stomatocytosis and increase blood viscosity. Br J Pharmacol 134:1207–1214PubMedCrossRef

15.

Iiýasova D, Mixon G, Wang F, Marcom PK, Marks J, Spasojevich I, Craft N, Arredondo F, Digiulio R (2009) Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration. Biomarkers 14(5):321–325CrossRef

16.

Chala E, Manes C, Iliades H, Skaragkas G, Mouratidou D, Kapantais E (2006) Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy. Hormones 5(2):137–146PubMed

17.

Halliwell B, Gutteridge JMC (2007) Free radicals in biology and medicine, 4th edn. Oxford University, New York

18.

Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126PubMedCrossRef

19.

Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:474–496CrossRef

20.

Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205PubMedCrossRef

21.

Repetto M, Reides C, Carretero MLG, Costa M, Griemberg G, Llesuy S (1996) Oxidative stress in blood of HIV infected patients. Clin Chim Acta 225:107–117CrossRef

22.

Simão ANC, Suzukawa AA, Casado MF, Oliveira RD, Guarnier FA, Cecchini F (2006) Genistein abrogates pre-hemolytic and oxidative stress damage induced by 2,2′-azobis (amidinopropane). Life Sci 78:1202–1210CrossRef

23.

Gonzales-Flecha B, Lleswy S, Boveris A (1991) Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver and muscle. Free Radic Biol Med 10:93–100CrossRef

24.

Panis C, Mazzuco TL, Costa CZF, Victorino VJ, Tatakihara VLH, Yamauchi LM, Yamada-Ogatta SF, Cecchini R, Pinge-Filho P (2011) Trypanosoma cruzi: effect of the absence of 5-lipoxygenase (5-LO)-derived leukotrienes on levels of cytokines, nitric oxide and iNOS expression in cardiac tissue in the acute phase of infection in mice. Exp Parasitol 127:58–65PubMedCrossRef

25.

Oliveira JA, Cecchini R (2000) Oxidative stress of liver in hamsters infected with Leishmania (L.) chagasic. J Parasitol 86(5):1067–1072PubMedCrossRef

26.

Reznick AZ, Packer L (1994) Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 1994(233):357–363CrossRef

27.

Miller GL (1959) Protein determination for large numbers of samples. Anal Chem 31:964CrossRef

28.

Bates DA, Winterbourn CC (1982) Reactions of Adriamycin with haemoglobin. Superoxide dismutase indirectly inhibits reactions of the adriamycin semiquinone. Biochem J 203:155–160PubMed

29.

Alexandre J, Batteux F, Nicco C, Chereau C, Laurent A, Guillevin L, Weill B, Goldwasser F (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119:41–48PubMedCrossRef

30.

Casado MF, Cecchini AL, Simão ANC, Oliveira RD, Cecchini R (2007) Free radical mediated pre-hemolytic injury in human red blood cells subjected to lead acetate as evaluated by chemiluminescence. Food Chem Toxicol 45:945–952PubMedCrossRef

31.

Lores-Arnais S, Llesuy S (1993) Oxidative stress in mouse heart by antitumoral drugs: a comparative study of doxorubicin, mitoxantrone. Toxicology 77(1–2):31–38

32.

Dumon MF, Freneix-Clerc M, Carbonneau MA, Thomas MJ, Perromat A, Clerc M (1994) Demonstration of the anti-lipid peroxidation effect of 3′,5′,7′, trihydroxy-4′ methoxy flavone rutinoside: in vitro study. Ann Biol Clin 52(4):265–270

33.

Barbosa DS, Cecchini R, El Kadri MZ, Dichi I (2003) Decrease oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition 19:837–841PubMedCrossRef

34.

Fossey J, Lefort D, Sorba J (1995) Free Radicals in Organic Chemistry. Wiley, New York

35.

Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271:C1424–C1437PubMed

36.

Geller DA, Billiar TR (1998) Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 17:7–23PubMedCrossRef

37.

Thomsen LL, Miles DW (1998) Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 17:107–118PubMedCrossRef

38.

Fukumura D, Kashiwagi S, Jain RK (2006) The role of nitric oxide in tumour progression. Nat Rev Cancer 6:521–534PubMedCrossRef

39.

Abdelmagid SA, Too CKL (2008) Prolactin and estrogen up-regulate carboxypeptidase-D to promote nitric oxide production and survival of MCF-7 breast cancer cells. Endocrinology 149:4821–4828PubMedCrossRef

40.

Saad SY, Najjar TA, Alashari M (2004) Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing administration. J Biochem Mol Toxicol 18(2):78–86PubMedCrossRef

41.

Awasthi S, Sharma R, Singhal SS, Zimniak P, Awasthi Y (2002) RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics. Drug Metab Dispos 30(12):1300–1310PubMedCrossRef

42.

Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983PubMedCrossRef

43.

Pfizer. Doxorubicin hydrochloride for injection. Available in: www.pfizer.com, access in Feb 22, 2011.

44.

Colombo T, Broggini M, Garattini S, Donell MG (1981) Differential adryamicin distribution to blood components. Eur J Drug Metab Pharmacokinet 6(2):115–122PubMedCrossRef

45.

Lang PA, Huober J, Bachman C, Kempe DS, Sobiesiak M, Akel A, Niemoeller OM, Dreischer P, Eisele K, Klarl BA, Gulbins E, Lang F, Wieder T (2006) Stimulation of erythrocyte phosphatidyl serine exposure by paclitaxel. Cell Physiol Biochem 18:151–164PubMedCrossRef

46.

Peres PS, Terra VA, Guarnier FA, Cecchini R, Cecchini AL (2011) Photoaging and chronological aging profile: understanding oxidation of the skin. J Photochem Photobiol B 103(2):93–97PubMedCrossRef

Titel: Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy
verfasst von: C. Panis
A. C. S. A. Herrera
V. J. Victorino
F. C. Campos
L. F. Freitas
T. De Rossi
A. N. Colado Simão
A. L. Cecchini
R. Cecchini
Publikationsdatum: 01.05.2012
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1693-x

Springer Medizin

Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Willingness to use tamoxifen to prevent breast cancer among diverse women

Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer

Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer

Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues

Disparities in breast cancer care delivery: solving a complex puzzle

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie